|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Biosimilars Series: Stakeholder Analysis
How successfully the biosimilar industry grows depends on the perception of stakeholders involved in drug prescription, dispensing and purchasing. This report presents an overview of the key decision makers and their opinion regarding biosimilar use.<
Biogenerics 2005: A New Level of Complexity
Biogenerics (or biosimilars, or follow-on proteins) could now enter the EU market in a matter of months, and the US by 2009. The prize awaiting biogeneric manufacturers such as Sandoz, Teva, and BioPartners is a global market worth $20 billion. Market
Biogenerics: Drivers and Resistors of Market Development
With several blockbuster biological products approaching patent expiry, the biogenerics segment represents an attractive opportunity for companies looking to escape intensifying competition in the commodity generics sector. The generics industry is pus
Strategies for Biogeneric Success
This report focuses on the specific strategies adopted by companies involved in the biogenerics arena, asking: - Why are specific strategies likely to be effective?
- Why are particular companies more likely to be successful in the
Biosimilars: Regulatory Issues
The drive for increased cost savings by healthcare providers is increasing the focus on boosting the biosimilar market. With a regulatory approval pathway in place in Europe and substantial guidelines to support biosimilar development, the European bi
Biosimilars: Benchmarking the key players
With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targeting the m
Results 1 - 10 of 10
|
|
|
|
